Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)

B-Cell Chronic Lymphocytic Leukemia Clinical Trial

Official title:

Phase I/II Trial of Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06364423
• Other study ID #: 10001599
• Secondary ID: 001599-C
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: June 26, 2024
• Est. completion date: July 1, 2030

Study information

• Verified date: April 11, 2024
• Source: National Institutes of Health Clinical Center (CC)
• Contact: Micaela A Ganaden, R.N.
• Phone: (240) 858-3654
• Email: micaela.ganaden[@]nih.gov
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background:

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are blood cancers that affect certain white blood cells. Advanced forms of these diseases are difficult to treat. CD19 is a protein often found on the surfaces of these cancer cells. Researchers can modify a person's own immune cells (T cells) to target CD19. When these modified T cells are returned to the body-a treatment called anti-CD19 chimeric antigen receptor (CAR) T cell therapy-they may help kill cancer cells.

Objective:

To test anti-CD19 CAR T cell therapy in people with CLL or SLL.

Eligibility:

People aged 18 years and older with CLL or SLL that has not been controlled with standard drugs.

Design:

Participants will be screened. They will have imaging scans and tests of their heart function. If a sample of tissue from their tumor is not available, a new one may be taken; the sample will be tested for CD19.

Participants will receive a drug to reduce the leukemia cells in their blood. Then they will undergo apheresis: Blood will be taken from the body through a needle. The blood will pass through a machine that separates out the T cells. The remaining blood will be returned to the body through a different needle. The collected T cells will be gene edited to make them attack cells with CD19.

Participants will take drugs to prepare them for treatment for 3 days. These drugs will start 5 days before the treatment. Then their own modified CAR T cells will be returned to their bloodstream. Participants will stay in the hospital for at least 9 days after the treatment.

Follow-up visits will continue for 5 years.

Description:

Background:

• Improved treatments for relapsed and refractory chronic lymphocytic leukemia (CLL) are needed.

• T cells can be genetically modified to express chimeric antigen receptors (CARs) that specifically target malignancy-associated antigens.

• Autologous T cells genetically modified to express CARs targeting the B-cell antigen CD19 have caused complete remissions in patients with leukemia or lymphoma. However, there is no FDA-approved CAR T-cell product for CLL. Responses to CAR T-cell therapy in CLL have historically been lower than in other B-cell malignancies.

• CD19 is uniformly expressed on CLL.

• CD19 is not expressed by normal cells except for B cells, follicular dendritic cells, and some plasma cells.

• We have constructed a novel gene therapy construct that encodes a fully-human anti-CD19 CAR.

• The conditioning regimen for this trial will include rituximab, fludarabine, and cyclophosphamide.

• Possible toxicities include cytokine-associated toxicities such as fever, hypotension, and neurological toxicities. Elimination of normal B cells is probable, and unknown toxicities are also possible.

Primary objective, Phase I:

-Determine the safety of administering a novel conditioning regimen and T cells expressing the Hu19-CD828Z CAR to participants with advanced CLL.

Primary objective, Phase II:

-Determine the overall response rate (ORR) of a novel conditioning regimen and T cells expressing the Hu19-CD828Z CAR for participants with advanced CLL.

Eligibility:

• Participant must have CLL or small lymphocytic lymphoma (SLL).

• Age >= 18 years of age at time of enrollment

• Participant must have malignancy that is measurable on a CT scan or by flow cytometry of bone marrow or blood.

• Participant must have a creatinine of 1.5 mg/dL or less and a normal cardiac ejection fraction.

• An ECOG performance status of 0-1 is required.

• No active infections are allowed including hepatitis B or hepatitis C.

• Absolute neutrophil count >= 1000/microL, platelet count >= 50,000/microL, hemoglobin >= 8g/dL

• Serum ALT and AST less or equal to 3 times the upper limit of the institutional normal unless liver involvement by malignancy is demonstrated.

• At least 14 days must elapse between the time of any prior systemic treatment (including corticosteroids) and the first dose of protocol-required rituximab. In addition, 60 days must elapse from therapy with antibody-based treatments targeting CD19 and CAR T-cell infusion.

• Prior CAR T-cell therapy is not allowed.

• Demonstration of CD19 expression by the CLL/SLL is required for eligibility.

• CD19 expression must be uniform . Uniform CD19 expression is defined as no obvious CD19-negative CLL/SLL being present.

Design:

• This is a phase I dose-escalation trial with an expansion cohort (Phase II portion)

• T cells obtained by leukapheresis will be genetically modified to express the Hu19-CD828Z CAR.

• Participants will receive 2 doses of rituximab and a lymphocyte-depleting chemotherapy conditioning regimen with the intent of decreasing the burden of CLL, which might reduce toxicity and improve anti-leukemia outcomes.

• Rituximab will be given in 2 doses, of 375 mg/m^2 for the first dose and 500 mg/m^2 for the second dose.

• The chemotherapy conditioning regimen is cyclophosphamide 500 mg/m^2 daily for 3 days and fludarabine 30 mg/m^2 daily for 3 days. Fludarabine will be given on the same days as the cyclophosphamide.

• Three days after the chemotherapy ends, participants will receive an infusion of CAR T cells.

• The initial dose level of this dose-escalation trial will be 1.0x10^6 CAR+ T cells/kg of recipient bodyweight.

• The CAR T-cell cell dose administered will be escalated until a maximum tolerated dose or an optimal dose is determined.

• Following the T-cell infusion, there is a mandatory 9-day inpatient hospitalization to monitor for toxicity.

• Outpatient follow-up is planned for 2 weeks and 1, 2, 3, 4, 6, 9, and 12 months after the CAR T-cell infusion; less frequent follow-up is required more than 1 year after infusion. Long-term gene-therapy follow-up for a total of 15 years after infusion is required.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 66
• Est. completion date: July 1, 2030
• Est. primary completion date: July 1, 2029
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 120 Years

Eligibility

• INCLUSION CRITERIA:

• Malignancy criteria

• Histologically confirmed participants with either CLL or SLL will be eligible.

• Demonstration of CD19 expression on CLL/SLL, as assessed by the NCI Laboratory of Pathology or NIH Department of Laboratory Medicine Hematopathology section.

• CD19 expression must be uniform meaning no populations of clearly CD19-negative CLL/SLL cells are observed.

• Participants must have received prior systemic therapy. The last dosage of systemic therapy (including corticosteroids) must be at least 14 days prior to the first dose of rituximab.

• For participants who have received antibodies targeting CD19, at least sixty days must elapse between therapy with antibodies targeting CD19 and CAR T-cell infusion.

• Participants must have received at least two prior treatment regimens at least one of which must have contained a Bruton s tyrosine kinase (BTK) inhibitor. Participants who took a BTK inhibitor but stopped due to intolerance are potentially eligible.

• All participants must have measurable malignancy as defined by at least one of the criteria below.

• Presence of CLL or SLL masses that are measurable (minimum 1.5 cm in largest diameter) by CT scan is required unless bone marrow or blood involvement with malignancy is detected. All masses must be less than or equal to 10.0 cm in the largest diameter.

• For CLL with only bone marrow and/or blood involvement, no mass is necessary, but if a mass is not present, bone marrow and/or blood malignancy must be detectable by flow cytometry. Any level of CLL detectable by flow cytometry is sufficient for enrollment.

• Other inclusion criteria:

• Age >= 18 years.

• Performance status (ECOG) 0-1.

• Participants must have adequate organ and marrow function as defined below:

• ANC >= 1,000/mcL without the support of filgrastim or other growth factors in the 10 days prior to enrollment

• platelets >= 50,000/mcL without transfusion support

• hemoglobin >= 8 g/dL

• total bilirubin <= 2.0 mg/dL

• ALT or AST Serum ALT and AST less or equal to 3 times the upper limit of the institutional normal unless liver involvement by malignancy is demonstrated. If liver involvement with malignancy is detected, ALT and AST must be less than or equal to 5 times the upper limit of normal

• Serum Creatinine Serum creatinine levels < 1.5 X institutional ULN. Participants with serum creatinine >= 1.5 X institutional ULN may participate if serum creatinine eGFR is >=50 mL/min/1.73m^2 by 2021 CKD-EPI equation.

• ALT (SGPT)=alanine aminotransferase (serum glutamic pyruvic transaminase);

• AST (SGOT)=aspartate aminotransferase (serum glutamic oxaloacetic transaminase); GFR=glomerular filtration rate; ULN=upper limit of normal.

• (A)Creatinine clearance (CrCl) or eGFR should be calculated per institutional standard.

• B cells must make up less than 90% of blood lymphocytes on a lymphocyte phenotyping profile TBNK at the time of enrollment.

• Room air oxygen saturation of 92% or greater

• Participants of child-bearing or child-fathering potential must be willing to practice abstinence or highly effective contraception from the time of enrollment on this study and for 12 months after receiving the protocol treatment, or until CAR T cells are no longer detectable in the blood, whichever is later.

• Participants must agree not to donate eggs for 12 months after receiving the protocol treatment, or until CAR T cells are no longer detectable in the blood, whichever is later.

• Participants who are breastfeeding must be willing to cease breastfeeding from time of enrollment until 6 months after receiving treatment, or until CAR T cells are no longer detectable in the blood, whichever is later.

• Participants must have a negative blood PCR test for hepatitis B DNA. If hepatitis B DNA (PCR) testing is not available, participants must have a negative hepatitis B surface antigen and negative hepatitis B core antibody test.

• Participants must have a negative blood PCR test for hepatitis C RNA. Only if Hepatitis C PCR testing is not available in a timely manner, participants must have a negative Hepatitis C antibody test.

• Cardiac ejection fraction of greater than or equal to 50% by echocardiography and no evidence of hemodynamically significant pericardial effusion as determined by an echocardiogram within 30 days prior to treatment start.

• All participants must have the ability to understand and willingness to sign a written informed consent.

• All participants must be willing to undergo mandatory biopsies during the study. A bone marrow biopsy will be required prior to the chemotherapy and CAR T-cell infusion. Another bone marrow biopsy will be required approximately 14 days after CAR T-cell infusion.

EXCLUSION CRITERIA:

• Participants who are receiving any other investigational agents.

• Participants who have had prior CAR T-cell therapy.

• Participants who have had a live-attenuated or viral vector-based vaccine in the last 60 days prior to pre-leukapheresis rituximab. Participants who plan to receive a live attenuated or viral vector-based vaccine within the first 100 days after CAR T-cell infusion.

• Participants that require urgent therapy due to tumor mass effects or spinal cord compression.

• Participants that have active hemolytic anemia.

• Current/active HIV infection, as measured by seropositivity for HIV antibody.

• Participants with second malignancies in addition to their CLL are not eligible if the second malignancy has required treatment with surgery, radiation or chemotherapy, or other therapies within the past 3 years or is not in complete remission. Exceptions are that, in the last 3 years, participants may have had successful resection of nonmetastatic basal cell or squamous cell carcinoma of the skin, and participants may have received hormonal therapy for fully resected breast cancer.

• Positive beta Human chorionic gonadotropin (Beta-HCG) serum or urine pregnancy test in women of childbearing potential (WOCBP) performed at screening.

• Active uncontrolled systemic infections (defined as infections causing fevers within 48 hours of the date of planned protocol rituximab or chemotherapy start and infections requiring intravenous antibiotics when intravenous antibiotics have been administered for less than 72 hours at the time of protocol rituximab or chemotherapy start). There must be objective evidence of infection, including, but not limited to, a positive blood, urine or sputum culture, positive nasal swab or blood test for viral infection, or the appearance of infiltrates on imaging of the lung.

• Active coagulation disorders or other major uncontrolled medical illnesses of the cardiovascular, respiratory, endocrine, renal, gastrointestinal, genitourinary or immune system, history of myocardial infarction, history of ventricular tachycardia or ventricular fibrillation, active cardiac arrhythmias (Resolved atrial fibrillation that is not treated with anticoagulants is allowed.), active obstructive or restrictive pulmonary disease, active autoimmune diseases such as rheumatoid arthritis.These include uncontrolled intercurrent illness manifesting as electrolyte derangements or as assessed by chemistries.

• Significant neurologic disorders, including a history of a seizure disorder as an adult, that are not completely and permanently resolved and not requiring current treatment.

• Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease).

• Prior allogeneic stem cell transplant

• Systemic corticosteroid steroid therapy of any dose greater than 5 mg/day or more of prednisone or equivalent is not allowed within 14 days prior to the first dose of rituximab. Corticosteroid creams, ointments, and eye drops are allowed.

• Participants on systemic anticoagulant therapy except aspirin.

• History of severe immediate hypersensitivity reaction to any of the agents used in this study, including hypersensitivity to aminoglycoside antibiotics, which may be used in the cell culture media.

• Active central nervous system/brain metastases or cerebrospinal fluid malignancy.

• Checkpoint inhibitor drugs such as pembrolizumab or nivolumab or other antibodies targeting PD-1 or PDL-1 within 180 days of protocol enrollment. This is because of possible effects checkpoint inhibitor therapy could have on the participant's T cells.

• Known active alcohol or drug abuse.

• History of allergy to study drug components.

• Active tumor lysis syndrome as assessed by serum uric acid, LDH, calcium, and phosphorus.

• Active rhabdomyolysis as assessed by elevated CK and acute change in renal function as reflected by increased creatinine and blood urea nitrogen (BUN).

• Active diabetic ketoacidosis or hyperosmolar hyperglycemic state, as assessed by serum glucose. The urine will be tested for ketones if serum glucose is over 350 mg/dL at screening.

Related Conditions & MeSH terms

• B-Cell Chronic Lymphocytic Leukemia
• B-Lymphocytic Leukemia, Chronic
• Leukemia
• Leukemia, B-Cell
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid

Intervention

Biological:
• Autologous HuCD19 ( Anti-CD19)CAR T cells
1.0x10^6 CAR+T-cells - 12x10^6 CAR+ T cells/kg (weight based dosing per cohort) infused on day 0

Drug:
• Cyclophosphamide
500 mg/m^2 IV infusion over 30 minutes on days -5, -4 and -3
• Fludarabine
30 mg/m^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3
• Rituximab
500 mg/m2 IV infusion over 30 minutes on day -5; 375 mg/m2 IV infusion over 30 minutes on days 2-9 prior to apheresis

Locations

Country	Name	City	State
United States	National Institutes of Health Clinical Center	Bethesda	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase I: Determine the safety of administering T-cells expressing a fully-human anti-CD19 CAR to participants with advanced CLL or SLL.	Adverse Events (AE) by type, grade, and frequency	From time of the pre-leukapheresis rituximab through 5 years after CAR T infusion.
Primary	Phase II: Determine the overall response rate (ORR) of T cells expressing an anti-CD19 CAR with a fully-human single chain variable fragment (scFv) to participants with advanced CLL	Overall Response Rate will be evaluated using published criteria; these will be reported along with a 95% confidence interval	From time of the pre-leukapheresis rituximab through 5 years after CAR T infusion.
Secondary	Phase I: Assess overall response rate	Overall Response rate (ORR= CR + PR) will be recorded if ORR occurs at any response assessment time-point.	up to 5 years
Secondary	Phase I+II: Assess complete response rate	Complete Response rate (CR) in participants who receive subsequent infusion, up to 5 years after entry date for last participant	up to 5 years
Secondary	Phase I+II: Assess duration of responses	Duration of response from date of response will be measured for no more than 5 years after the last participant has been enrolled on the trial.	up to 5 years
Secondary	Phase I+II: Determine the ORR for re treatment with rituximab, chemotherapy and CAR T cells in eligible patients	Overall Response rate (ORR= CR + PR) for re-treatment with Rituximab will be recorded if ORR occurs at any response assessment time-point.	up to 5 years
Secondary	Phase II: Determine the frequency of grade 3-4 adverse events at the Optimal Dose	Adverse Events (AE) by type, grade, and frequency	up to 5 years

External Links

•   NIH Clinical Center Detailed Web Page